NDLI: Reports of suicidality in clinical trials of montelukast.

Please wait, while we are loading the content...

Year: 2017 Volume: 139

Year: 2016 Volume: 138

Year: 2016 Volume: 137

Year: 2015 Volume: 136

Year: 2015 Volume: 135

Year: 2014 Volume: 134

Year: 2014 Volume: 133

Year: 2013 Volume: 132

Year: 2013 Volume: 131

Year: 2012 Volume: 130

Year: 2012 Volume: 129

Year: 2011 Volume: 128

Year: 2011 Volume: 127

Year: 2010 Volume: 126

Year: 2010 Volume: 125

Year: 2009 Volume: 124

Year: 2009 Volume: 124 Issue: 6

Year: 2009 Volume: 124 Issue: 6 Supplementary

Year: 2009 Volume: 124 Issue: 5

Year: 2009 Volume: 124 Issue: 4

Prostaglandin E(2)-EP(3) signaling suppresses skin inflammation in murine contact hypersensitivity.

Summary of the 2008 National Institute of Allergy and Infectious Diseases-US Food and Drug Administration Workshop on Food Allergy Clinical Trial Design.

Anaphylactic reaction to (mixed) fruit juice containing dragon fruit.

Critical role of IgE-dependent mast cell activation in a murine model of allergic conjunctivitis.

Vitamin C for the common cold should not be rejected on the basis of old and erroneous articles.

Phenotypic determinants of uncontrolled asthma.

Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes.

Polyethylene glycol-modified adenosine deaminase improved lung disease but not liver disease in partial adenosine deaminase deficiency.

Lipid transfer protein (Ara h 9) as a new peanut allergen relevant for a Mediterranean allergic population.

Domestic use of hypochlorite bleach, atopic sensitization, and respiratory symptoms in adults.

Serum tryptase levels in atopic and nonatopic children.

Higher incidence of pediatric anaphylaxis in northern areas of the United States.

Induction of IL-10-producing regulatory T cells with TCR diversity by epitope-specific immunotherapy in pollinosis.

Cats and dogs and the risk of atopy in childhood and adulthood.

Plasmacytoid dendritic cells during infancy are inversely associated with childhood respiratory tract infections and wheezing.

Recommendations for appropriate sublingual immunotherapy clinical trials.

Cyclosporin A reduces CD4(+)CD25(+) regulatory T-cell numbers in patients with atopic dermatitis.

Reduced central tolerance in Omenn syndrome leads to immature self-reactive oligoclonal T cells.

The minimally important difference of the Asthma Control Test.

A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously.

Expression of chemokines and chemokine receptors in lesional and nonlesional upper skin of patients with atopic dermatitis.

Elevated serum cytokines during human anaphylaxis: Identification of potential mediators of acute allergic reactions.

Exhaled nitric oxide levels in asthma: Personal best versus reference values.

The LOCAL Study: Local reactions do not predict local reactions in allergen immunotherapy.

Natural killer T cells in bronchial biopsies from human allergen challenge model of allergic asthma.

The occupant as a source of house dust bacteria.

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.

Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma.

The acetaminophen and asthma hypothesis 10 years on: A case to answer.

Thymic stromal lymphopoietin induction by polyinosinic:polycytidylic acid in human keratinocytes is preferentially mediated through protein kinase R and retinoid-inducible gene I and not Toll-like receptor 3.

Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated with aspirin desensitization.

Associations between prenatal pesticide exposure and cough, wheeze, and IgE in early childhood.

Anaphylaxis: Recent advances in assessment and treatment.

Mechanisms of mast cell signaling in anaphylaxis.

Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant.

Sexual dimorphism: Is it relevant to steroid resistance or asthma control?

Reports of suicidality in clinical trials of montelukast.

Assessing risk: Data from montelukast clinical trials.

Analysis of behavior-related adverse experiences in clinical trials of montelukast.

Does exposure to cats and dogs decrease the risk of allergic sensitization and disease?

Exaggerated IL-17 response to epicutaneous sensitization mediates airway inflammation in the absence of IL-4 and IL-13.

Induction of long-lived allergen-specific plasma cells by mucosal allergen challenge.

Year: 2009 Volume: 124 Issue: 3

Year: 2009 Volume: 124 Issue: 3 Supplementary

Year: 2009 Volume: 124 Issue: 3 Supplementary 2

Year: 2009 Volume: 124 Issue: 2

Year: 2009 Volume: 124 Issue: 2 Supplementary

Year: 2009 Volume: 124 Issue: 1

Year: 2009 Volume: 123

Year: 2008 Volume: 122

Year: 2008 Volume: 121

Year: 2007 Volume: 120

Year: 2007 Volume: 119

Year: 2006 Volume: 118

Year: 2006 Volume: 117

Year: 2005 Volume: 116

Year: 2005 Volume: 115

Year: 2004 Volume: 113

Year: 2001 Volume: 108

Year: 2000 Volume: 106

Reports of suicidality in clinical trials of montelukast.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Philip, George Hustad, Carolyn Noonan, Gertrude Malice, Marie-Pierre Ezekowitz, Alan Reiss, Theodore F. Knorr, Barbara
Description	Country affiliation: United States Author Affiliation: Philip G ( Merck & Co, Inc, North Wales, Pa. 19454, USA. george_philip@merck.com)
Abstract	BACKGROUND: In recent years, a number of drugs and drug classes have come under scrutiny by the US Food and Drug Administration regarding suicidality (including suicidal behavior and ideation). OBJECTIVE: We sought to perform 2 reviews (requested by the US Food and Drug Administration) of the number of events possibly related to suicidality reported in Merck clinical trials of montelukast. METHODS: Method 1 was a descriptive review of clinical adverse experiences (AEs) from 116 studies (double-blind and open-label, adult and pediatric, and single- and multiple-dose studies) completed as of March 2008. Summaries were constructed from investigator-reported AE terms possibly related to suicidality (completed suicide, suicide attempt, and suicidal ideation) or self-injurious behavior. Method 2 used a retrospective adjudication of investigator-reported AEs and other events listed in the study database described as possibly suicidality-related adverse events (PSRAEs) in a prespecified set of 41 double-blind, placebo-controlled trials completed as of April 2008. RESULTS: No completed suicides were reported in any study. For the descriptive review, 20,131 adults and children received montelukast, 9,287 received placebo, and 8,346 received active control; AEs possibly related to suicidality were rare and were similar between the montelukast and placebo or active-control groups. For the adjudicated review across 22,433 patients, there were 730 adjudicated events. In 9,929 patients taking montelukast, 1 PSRAE was identified (classified as suicidal ideation); none were identified in 7,780 and 4,724 patients taking placebo and active control, respectively. CONCLUSIONS: Assessed by using 2 complementary methods, there were no reports of completed suicide, and reports of PSRAEs were rare in patients receiving montelukast and similar to those seen in control subjects.
File Format	HTM / HTML
ISSN	00916749
e-ISSN	10976825
Journal	Journal of Allergy and Clinical Immunology
Issue Number	4
Volume Number	124
Language	English
Publisher	Elsevier
Publisher Date	2009-10-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Immunology Acetates Adverse Effects Anti-asthmatic Agents Asthma Drug Therapy Leukotriene Antagonists Quinolines Self-injurious Behavior Epidemiology Suicide Therapeutic Use Complications Immunology Mental Disorders Chemically Induced Retrospective Studies Risk Assessment Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in